Elsholtz, Fabian Henry Jürgen http://orcid.org/0000-0001-5258-3250
Erxleben, Christoph
Bauknecht, Hans-Christian
Dinkelborg, Patrick
Kreutzer, Kilian
Hamm, Bernd
Niehues, Stefan Markus
Funding for this research was provided by:
Projekt DEAL
Article History
Received: 8 October 2020
Revised: 17 December 2020
Accepted: 18 January 2021
First Online: 3 February 2021
Change Date: 19 April 2021
Change Type: Update
Change Details: The funding note was missing: Open Access funding enabled and organized by Projekt DEAL.
Declarations
:
: The scientific guarantor of this publication is Fabian Henry Jürgen Elsholtz.
: Bernd Hamm declares relationships with the following companies: Abbott, Actelion Pharmaceuticals, Bayer Schering Pharma, Bayer Vital, BRACCO Group, Bristol Myers Squibb, Charité Research Organisation GmbH, Deutsche Krebshilfe, Dt. Stiftung für Herzforschung, Essex Pharma, EU Programmes (Past President of ESR), Fibrex Medical Inc., Focused Ultrasound Surgery Foundation, Fraunhofer Gesellschaft, Guerbet, INC Research, InSightec Ltd., IPSEN Pharma, Kendle/MorphoSys AG, Lilly GmbH, Lundbeck GmbH, MeVis Medical Solutions AG, Nexus Oncology, Novartis, Parexel CRO Service, Perceptive, Pfizer GmbH, Phillips, Sanofi-Aventis S.A., Siemens, Spectranetics GmbH, Terumo Medical Corporation, TNS Healthcare GmbH, Toshiba, UCB Pharma, Wyeth Pharma, Zukunftsfonds Berlin (TSB).Stefan Markus Niehues declares relationships with the following companies: Vital Images, Canon Medical Systems, Guerbet, Bracco Imaging, Teleflex/Vidacare.The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
: No complex statistical methods were necessary for this paper.
: Written informed consent was obtained from all patients in this study.
: Institutional Review Board approval was obtained.
: • retrospective• diagnostic or prognostic study• performed at one institution